The Frederick National Laboratory for Cancer Research (FNLCR) is an integral part of an aggressive national initiative
to further scientific understanding of cancers driven by mutations of the RAS family of genes. Established by
the National Cancer Institute (NCI), the RAS Initiative seeks to facilitate connections between and among researchers, bringing new ideas and technologies
to bear on RAS.
The RAS Initiative supports the development of therapies against tumors that contain mutations in members of the RAS family of oncogenes. In contrast
to progress in other areas of cancer therapeutics, researchers have not successfully developed effective treatments against proteins produced by RAS
oncogenes. RAS genes are mutated in about one-third of all cancers, including most pancreatic adenocarcinomas, about 45 percent of colorectal
cancers, and about 35 percent of lung adenocarcinomas. To address this challenge, the RAS Initiative was launched as a large-scale collaboration to identify
therapeutic strategies for patients with RAS-driven cancers. The Advanced Technology Research Facility at the Frederick National Lab serves as the program hub that
engages academia, the pharmaceutical industry, and NCI intramural labs as collaborating spokes in the RAS Initiative.
Learn more about funding opportunities and other details of the initiative by going to the National Cancer Institute’s RAS Central page: https://www.cancer.gov/research/key-initiatives/ras/spokes-funding.
Typed the characters seen in the image below to continue.
Sending Mail ...